• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

5 Small Biotechs Receive Shots in the Arm

Favorable quarterly results and FDA drug approvals should help lift these five names.
By BRET JENSEN
Nov 12, 2017 | 12:00 PM EST
Stocks quotes in this article: SGYP, OMER, BDSI, ENDO, HRTX, DVAX, MRK

After the bell on Thursday we got a handful of earnings reports and a couple U.S Food and Drug Administration (FDA) approvals among the small-cap biotech names I often cover in these posts, so let's look at some of the highlights.

Synergy Pharmaceuticals Inc. (SGYP) posted very solid third-quarter results that beat both top- and bottom-line consensus. Its key drug Trulance continues to ramp up impressively since it first hit the market this March. Scripts more than doubled from the second quarter. The drug should be approved for irritable bowel syndrome with constipation (IBS-C) in January, expanding its potential market by a third. Greater access to insurer programs and Medicare formularies to begin 2018 should boost Trulance's sale trajectory further. A buyout in 2018 is certainly on potential end game for this name.

Omeros Corp. (OMER) also reported numbers that easily beat both top- and bottom-line expectations. Sales of its drug Omidria triggered a more than 90% year-over-year increase in revenues. OMS721, which has blockbuster potential and is in trials for five indications, continues to progress nicely. In the quarter, the FDA granted OMS721 orphan drug designation in IgA nephropathy, which should enter Phase 3 development soon.

The turnaround at BioDelivery Sciences International Inc. (BDSI) continues to gain traction. Third-quarter results came in slightly better than expected. The company has done a wonderful job marketing Belbuca since it received that now wholly owned drug back from previous distribution partner Endo International plc (ENDO) at the end of 2016 as that firm dissolved its pain management practice. Sales of Belbuca were the key reason revenues more than tripled this third quarter from the same period a year ago. Scripts grew 15% sequentially this quarter as well.

Heron Therapeutics Inc. (HRTX) had its compound Cinvanti approved by the FDA for the prevention of acute and delayed nausea and vomiting associated with chemotherapy in adult patients. The reaction in the after-hours market was muted as approval was expected and the company is expected to do a secondary offering to raise more financing on the news. I still like Heron from a longer-term perspective and will be adding on any dip a secondary announcement triggers.

Last but certainly not least, the hepatitis B vaccine Heplisav-B finally was approved by the FDA. The approval ends a five-year saga for Dynavax Technologies Corp. (DVAX) getting this biologic over the finish line. The vaccine is clearly superior to the current standard both in protection rates and compliance. Heplisav-B easily could see $500 million or better in peak sales just in the United States.

The stock will be up today and will have roughly quintupled off its lows in the first quarter of this year. However, I think the shares can get past $30 provided the company signs a large distribution and marketing deal around Heplisav-B with a drug giant with a significant footprint in vaccines such as Merck & Co. (MRK) and if Dynavax's oncology asset SD-101 continues to show encouraging results when mid-stage data is released in the first quarter of next year.

This commentary originally appeared on Real Money Pro on Nov. 10. Click here to learn about this dynamic market information service for active traders.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jensen was long BDSI, DVAX, HRTX, OMER and SGYP.

TAGS: Investing | U.S. Equity | Healthcare | Earnings | How-to

More from Healthcare

There Are Market Bright Spots, but I View the July Rally as a Head Fake

Bret Jensen
Aug 3, 2022 10:30 AM EDT

It's hard to see stock valuations rising when inflation remains high and the economy appears headed for a recession if it isn't in one already.

A Recession Appears Inevitable, but There Are Still Places to Invest

Bret Jensen
Jul 27, 2022 10:30 AM EDT

A few homebuilders and healthcare stocks seem likely to hold up better than most of the market in a recession.

Change Healthcare Continues to Knock on a Breakout Level

Bruce Kamich
Jul 25, 2022 11:25 AM EDT

The CHNG chart is at an interesting juncture.

The Healing Process Begins for Cano Health

Bruce Kamich
Jul 21, 2022 1:30 PM EDT

Here's how to approach CANO as the shares have made a bottom formation.

With HCA Healthcare, I'm Getting Healthy Indications

Bruce Kamich
Jul 21, 2022 9:20 AM EDT

The healthcare provider is set to report earnings Friday.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:24 AM EDT PETER TCHIR

    Jobs Report Reaction: Incredibly Strong, But Questions to Ask

    An incredibly strong July jobs report. Not only d...
  • 08:54 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The Secret to Dealing With FOMO
  • 03:51 PM EDT REAL MONEY

    AMD Second-Quarter Earnings Live Blog

    Real Money's Eric Jhonsa covers 's second-quarte...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login